Clinical Trial Update: Extension Study to Evaluate the Long-Term Safety and Tolerability of MBX 2109 in Patients With Hypoparathyroidism [Phase 2]

View source ↗

Summary

An extension study is planned to evaluate the long-term safety and tolerability of MBX 2109 in patients with hypoparathyroidism. The trial is Phase 2 and curren…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypoparathyroidism

Drugs mentioned

• MBX 2109 (MBX-2109)

Snippet

Sponsor: MBX Biosciences | Conditions: Hypoparathyroidism | Phase 2 | Status: ACTIVE_NOT_RECRUITING